MARKET

ATTO

ATTO

Attovia Therapeutics Inc
NASDAQ
22.79
+0.26
+1.15%
After Hours: 22.79 0 0.00% 19:30 09/11 EDT
OPEN
22.43
PREV CLOSE
22.53
HIGH
24.22
LOW
22.00
VOLUME
175.77K
TURNOVER
--
52 WEEK HIGH
28.00
52 WEEK LOW
16.15
MARKET CAP
1.04B
P/E (TTM)
-24.9234
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ATTO last week (0831-0904)?
Weekly Report · 6d ago
Primary Markets Group August IPO Update
Seeking Alpha · 09/05 06:30
5 Biotech And Medical Device Stocks In Focus: Pro-Dex, Modular Medical, ENvue Medical & More
NASDAQ · 09/04 18:36
Quanex Building Products, Concrete Pumping, SanDisk And Other Big Stocks Moving Higher On Friday
Benzinga · 09/04 15:26
Analysts Offer Insights on NA Companies: Attovia Therapeutics, Inc. (ATTO) and Navan, Inc. Class A (NAVN)
TipRanks · 09/04 10:30
Biotech Stocks At 52-Week Highs - ATTO, HALO, IKT, TVTX, ATRC
NASDAQ · 09/04 09:15
Attovia's Q2 Loss Expands With Increased Trials For ATTO-1310; Plans Phase 2 For Q1 '27
NASDAQ · 09/03 16:47
Sam Slutsky Reiterates Buy on Attovia, Maintains $45 Price Target on Strong Early ATTO-1310 Data and Robust Cash Runway
TipRanks · 09/03 15:55
More
About ATTO
Attovia Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases with high unmet need. Its lead pipeline candidates target commercially validated pathways and are designed through its ATTOBODY biologics platform to deliver improved treatments relative to the standards of care. Its ATTOBODY platform uses an evolution-driven, high-throughput process which allows for discovery and creation of a high diversity of potential product candidates. It is developing a pipeline of novel biotherapeutics for the treatment of immune-mediated diseases. Its first two product candidates for its immune-dermatology franchise, ATTO-1310 and ATTO-2306, have the potential to treat patients suffering from pruritic and lesional diseases. Its third program, ATTO-1091, broadens its reach to other inflammatory diseases, such as IBD, a therapeutic area with substantial unmet need. ATTO-1310 is an ATTOBODY-based therapeutic targeting interleukin-31.

Webull offers Attovia Therapeutics stock information, including NASDAQ: ATTO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATTO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATTO stock methods without spending real money on the virtual paper trading platform.